Cargando…

Immunological Analysis of Vestibular Schwannoma Patients

BACKGROUND: Vestibular schwannoma is a benign intracranial tumor of the vestibulocochlear nerve. Although it is a well-known pathology, growth factors and cytokine changes in vestibular schwannoma patients have not been totally elucidated. The objective of our study was to evaluate the concentration...

Descripción completa

Detalles Bibliográficos
Autores principales: Borysenko, Oleg, Melnykov, Oleg, Prilutskaya, Alexandra, Buracovschi, Marin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Academy of Otology and Neurotology and the Politzer Society 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984973/
https://www.ncbi.nlm.nih.gov/pubmed/36718028
http://dx.doi.org/10.5152/iao.2023.22581
_version_ 1784900852812611584
author Borysenko, Oleg
Melnykov, Oleg
Prilutskaya, Alexandra
Buracovschi, Marin
author_facet Borysenko, Oleg
Melnykov, Oleg
Prilutskaya, Alexandra
Buracovschi, Marin
author_sort Borysenko, Oleg
collection PubMed
description BACKGROUND: Vestibular schwannoma is a benign intracranial tumor of the vestibulocochlear nerve. Although it is a well-known pathology, growth factors and cytokine changes in vestibular schwannoma patients have not been totally elucidated. The objective of our study was to evaluate the concentration changes of transforming growth factor beta1, vascular endothelial growth factor, immunoglobulins A, M, and carcinoembryonic antigen in vestibular schwannoma patients. METHODS: In our study, we performed an immunological analysis of 35 patients with vestibular schwannoma of different stages. According to the evolution of vestibular schwannoma, 20 patients did not show tumor growth, but 15 patients had a growing tumor. RESULTS: The level of vascular endothelial growth factor in the blood serum of study groups exceeded the control values by 8 times and transforming growth factor beta1 by 1.65. Increased values of immunoglobulin A and immunoglobulin M were observed in patients with intracanal, second, and third stages of tumor, compared with the control group. Carcinoembryonic antigen was found to be of increased values in patients with intracanal and third-stage vestibular schwannoma, in comparison to the control group. CONCLUSION: Growth factors such as vascular endothelial growth factor and transforming growth factor beta1 can play a significant role in the genesis of vestibular schwannoma. In vestibular schwannoma patients, their investigation is appropriate both in the process of monitoring and in the assessment of treatment effectiveness. Immunoglobulins M and A can be used as additional markers of vestibular schwannoma, especially in tumor growth. Carcinogenic embryonic antigen has high values only in the late stages of vestibular schwannoma development.
format Online
Article
Text
id pubmed-9984973
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher European Academy of Otology and Neurotology and the Politzer Society
record_format MEDLINE/PubMed
spelling pubmed-99849732023-03-05 Immunological Analysis of Vestibular Schwannoma Patients Borysenko, Oleg Melnykov, Oleg Prilutskaya, Alexandra Buracovschi, Marin J Int Adv Otol Original Article BACKGROUND: Vestibular schwannoma is a benign intracranial tumor of the vestibulocochlear nerve. Although it is a well-known pathology, growth factors and cytokine changes in vestibular schwannoma patients have not been totally elucidated. The objective of our study was to evaluate the concentration changes of transforming growth factor beta1, vascular endothelial growth factor, immunoglobulins A, M, and carcinoembryonic antigen in vestibular schwannoma patients. METHODS: In our study, we performed an immunological analysis of 35 patients with vestibular schwannoma of different stages. According to the evolution of vestibular schwannoma, 20 patients did not show tumor growth, but 15 patients had a growing tumor. RESULTS: The level of vascular endothelial growth factor in the blood serum of study groups exceeded the control values by 8 times and transforming growth factor beta1 by 1.65. Increased values of immunoglobulin A and immunoglobulin M were observed in patients with intracanal, second, and third stages of tumor, compared with the control group. Carcinoembryonic antigen was found to be of increased values in patients with intracanal and third-stage vestibular schwannoma, in comparison to the control group. CONCLUSION: Growth factors such as vascular endothelial growth factor and transforming growth factor beta1 can play a significant role in the genesis of vestibular schwannoma. In vestibular schwannoma patients, their investigation is appropriate both in the process of monitoring and in the assessment of treatment effectiveness. Immunoglobulins M and A can be used as additional markers of vestibular schwannoma, especially in tumor growth. Carcinogenic embryonic antigen has high values only in the late stages of vestibular schwannoma development. European Academy of Otology and Neurotology and the Politzer Society 2023-01-01 /pmc/articles/PMC9984973/ /pubmed/36718028 http://dx.doi.org/10.5152/iao.2023.22581 Text en 2023 authors https://creativecommons.org/licenses/by-nc/4.0/ Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Original Article
Borysenko, Oleg
Melnykov, Oleg
Prilutskaya, Alexandra
Buracovschi, Marin
Immunological Analysis of Vestibular Schwannoma Patients
title Immunological Analysis of Vestibular Schwannoma Patients
title_full Immunological Analysis of Vestibular Schwannoma Patients
title_fullStr Immunological Analysis of Vestibular Schwannoma Patients
title_full_unstemmed Immunological Analysis of Vestibular Schwannoma Patients
title_short Immunological Analysis of Vestibular Schwannoma Patients
title_sort immunological analysis of vestibular schwannoma patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984973/
https://www.ncbi.nlm.nih.gov/pubmed/36718028
http://dx.doi.org/10.5152/iao.2023.22581
work_keys_str_mv AT borysenkooleg immunologicalanalysisofvestibularschwannomapatients
AT melnykovoleg immunologicalanalysisofvestibularschwannomapatients
AT prilutskayaalexandra immunologicalanalysisofvestibularschwannomapatients
AT buracovschimarin immunologicalanalysisofvestibularschwannomapatients